These backgrounders provide more in-depth information on various topics related to insulin degludec including:

Insulin degludec is an ultra-long-acting basal insulin being developed by Novo Nordisk. Insulin degludec and insulin degludec / insulin aspart have been submitted to regulatory authorities for review but have not yet been approved for use.

APROM ID# 4045. Date of Approval: May 2012